# Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

> **NCT01265849** · PHASE3 · COMPLETED · sponsor: **CEL-SCI Corporation** · enrollment: 928 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Oral Cavity
- Squamous Cell Carcinoma of the Soft Palate

## Interventions

- **BIOLOGICAL:** LI
- **DRUG:** Cyclophosphamide
- **DRUG:** Indomethacin
- **DIETARY_SUPPLEMENT:** Zinc
- **PROCEDURE:** Surgery
- **DRUG:** Cisplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT01265849
- **Lead sponsor:** CEL-SCI Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2020-05-15
- **Final completion:** 2020-12-04
- **Target enrollment:** 928 (ACTUAL)
- **Last updated:** 2022-08-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01265849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01265849, "Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01265849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*